Details for Patent: 9,358,240

Which drugs does patent 9,358,240 protect, and when does it expire?

Patent 9,358,240 protects TYVASO and is included in one NDA.

This patent has twelve patent family members in seven countries.

Summary for Patent: 9,358,240

Title:	Treprostinil administration by inhalation
Abstract:	Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.
Inventor(s):	Olschewski; Horst (Graz, AT), Roscigno; Robert (Chapel Hill, NC), Rubin; Lewis J. (LaJolla, CA), Schmehl; Thomas (Giessen, DE), Seeger; Werner (Giessen, DE), Sterritt; Carl (Weybridge, GB), Voswinckel; Robert (Giessen, DE)
Assignee:	United Therapeutics Corporation (Silver Spring, MD)
Application Number:	12/591,200
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,358,240
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 9,358,240

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
United Therap	TYVASO	treprostinil	SOLUTION;INHALATION	022387-001	Jul 30, 2009		RX	Yes	Yes						METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE

International Family Members for US Patent 9,358,240

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2654492
China	101495122
European Patent Office	2026816
Spain	2707548